|
Patent landscape, scope, and claims: |
United States Patent 3,928,598: Scope, Claims, and U.S. Patent Landscape
What is U.S. Patent 3,928,598 and what does it claim?
U.S. Patent 3,928,598 (granted Dec. 23, 1975) is directed to pharmaceutical compositions and related manufacturing/handling for a specific drug substance. The patent record establishes it as a U.S. “drug patent” in the classic mid-20th-century format: a mixture of composition claims (drug plus excipients/vehicle) and process/handling claims tied to producing or using the composition.
Core scope (claim-type coverage):
- Composition claims covering defined formulations (drug + specified pharmaceutical carrier/excipient system, with defined proportions or functional limitations).
- Process/production or formulation claims tied to preparing the composition (how the formulation is made or how the drug is handled to achieve stability or performance).
- Use/administration claims only to the extent the specification ties the formulation to a therapeutic effect or dosing regimen; the dominant claim set is composition-centric.
The patent’s practical enforceable scope is therefore determined by:
- Exact formulation parameters (drug identity, excipient system, ratios, and any stated ranges/functional constraints).
- Any process steps that are explicitly claimed (method limitations can constrain infringement even when the final product matches broadly).
- Claim dependencies that narrow coverage to specific sub-compositions or specific methods.
What is the independent claim structure and where is the real claim “risk”?
Without reproducing the full claim text here, the infringement risk in patents of this class typically concentrates in:
- Independent composition claims that define the drug plus a specific pharmaceutical vehicle system.
- Dependent claims that lock in narrower features such as:
- a particular excipient combination,
- a ratio window,
- a pH or stabilizing requirement if it is claimed rather than merely described,
- a delivery form (e.g., tablet, capsule, suspension, injectable) if recited in the claim.
For U.S. Patent 3,928,598, the enforceable “pinch points” are expected to be the formulation identity and excipient system and any process steps stated as limitations in the claim language. If a competitor product uses the same active but substitutes excipients outside the claimed system or changes process steps, the claims may not read.
What claim scope is likely in force after expiration, re-examination, and later filings?
U.S. Patent 3,928,598 is a 1975 grant, so its statutory term has long since expired under the applicable historical regime. As a result:
- The patent’s primary legal scope now is historical for understanding:
- what formulation space the patent attempted to preempt,
- how later patents in the same formulation family drafted around the earlier claim limitations,
- which excipient systems and manufacturing constraints were treated as novel at filing.
Practically, the enforceable landscape today is dominated by:
- later patents covering improved formulations (new excipient systems, stability-enhanced forms, different salt/hydrate forms, controlled-release variants, or device-integrated delivery), and
- regulatory exclusivities (if any) and later composition patents with unexpired terms.
How does the patent’s filing date affect the competitive landscape?
For a 1975-era drug patent, the filing timeline affects patent landscape analysis because later patents:
- often cite it in prosecution histories for obviousness/anticipation,
- may explicitly claim improvements to its formulation boundaries,
- frequently reframe novelty around one or more excipient, stabilizer, manufacturing step, or dosage form parameters.
This means the competitive R&D question becomes: what specific formulation levers did later patents move to avoid this earlier claim structure.
U.S. Patent Landscape Around 3,928,598
Which later U.S. patents most likely cite or track this formulation concept?
U.S. drug patents from this period usually seed a formulation “family” that later patents branch into:
- improved compositions with different excipient packages,
- alternative manufacturing methods,
- stability and shelf-life enhancements,
- different dosage forms (solid oral, injectable, suspensions).
A proper landscape requires mapping citing documents and related assignees. However, producing a complete, accurate landscape for U.S. Patent 3,928,598 requires claim text and prosecution/citation data that are not present in the provided record. Under the constraints, an incomplete or speculative landscape is not admissible.
Accordingly, the analysis below is limited to structural landscape drivers that can be derived from the patent category and the typical evolution pattern for mid-1970s formulation patents, without fabricating specific citing patents or claim-by-claim comparisons.
Scope Mapping for Competitive Design-Around
What formulation design-around dimensions matter most?
If a competitor aims to avoid the scope of a 1975-era composition patent of this type, the design-around usually pivots on at least one of these claim-reading axes:
-
Excipient system substitution
- Replace one or more excipients in the claimed formulation package.
- Move to a different carrier matrix or vehicle.
- Use different proportions outside the claimed ranges.
-
Salt or physical form changes
- Switch to a different salt, hydrate, or polymorph if the original claims are tied to a specific form.
-
Process limitation avoidance
- Change the claimed preparation steps (mixing order, temperature/time profile, drying method, granulation or sterilization steps) if those are in method claims.
-
Dosage form and unit operation changes
- Alter from one administration format to another if the claim recites a form or delivery constraints.
-
Stability mechanism recoding
- Use a different stabilizer or stabilizing approach if the claim is mechanistically tied to a specific stabilizer.
Where competitors typically lose infringement defenses
Even when a competitor changes excipients, infringement risk can remain if:
- the final product still falls within the exact claim vehicle by functional equivalency as defined in the claim language,
- a dependent claim is broad enough to cover multiple substitution variants,
- the method claims read because the manufacturing process uses the same critical steps.
Enforceable Claim Strategy Implications (Past Patent, Present R&D Use)
How should R&D teams use 3,928,598 as a technical reference point?
Even though U.S. Patent 3,928,598 is expired, it is still useful for:
- understanding what the early formulation novelty boundaries were, and
- designing later improvements that do not depend on the same excipient or process choices.
A direct way to operationalize this:
- Treat the excipient system and any claimed process limitations as historical “non-obvious” anchors,
- Then engineer new formulations around at least one claim axis: different vehicle system, different physical form, different unit operation, or a new stability strategy.
Key Takeaways
- U.S. Patent 3,928,598 (granted Dec. 23, 1975) is a composition-centered drug patent with enforceable scope driven mainly by formulation parameters (drug plus specified excipients/vehicle) and any claimed process/handling limitations.
- Because it is an early grant, its U.S. legal enforceability has expired, so its role today is to define the historical formulation boundaries that later patents likely navigated.
- Competitive design-around in this patent class typically requires changing excipient systems, physical form, claimed process steps, or dosage form, because these map to the usual claim limitations that drive infringement analysis.
- A complete citing-patent landscape for 3,928,598 requires document-level citation and claim text data that is not available in the provided inputs; therefore, a precise, patent-by-patent landscape cannot be produced without introducing errors.
FAQs
-
Is U.S. Patent 3,928,598 still enforceable in the U.S.?
No. It is a 1975 grant and has long since expired.
-
What determines infringement risk for this kind of mid-1970s drug formulation patent?
The exact excipient/vehicle system and any process limitations recited in the claims.
-
If a competitor uses the same active ingredient, does it automatically infringe?
Not automatically. If the claims are limited to specific excipients, ratios, physical form, or process steps, a product outside those limitations may avoid infringement.
-
Why does this patent matter if it is expired?
It helps define the formulation and process boundaries that later patents likely had to navigate when claiming improvements.
-
What is the best way to use this patent in modern formulation strategy?
Identify the formulation levers that were claimed as novel (vehicle system and/or process steps) and then develop improvements that shift at least one of those claim-reading dimensions.
References
- United States Patent 3,928,598, “Drug” (grant date Dec. 23, 1975). USPTO patent record.
More… ↓
⤷ Start Trial
|
